Epi One March Update

Mar 4, 2025

Epi One CEO Michael Marquardt provides an update on the latest news on developments in our current laboratory, our search for additional lab space in Delaware, expansion of our research team, and partnerships with medical centers around the country for clinical validation.

 

MORE NEWS

American Cancer Society Medal of Honor Ceremony

Epi One CEO Michael Marquardt had the privilege of attending the American Cancer Society Medal of Honor ceremony ...

Epi One to Present Poster Session at AACR Conference

We are delighted to confirm that we will be presenting a poster session at this year's American Association ...

Epi One Raises $2.1 Million in Successful Equity Crowdfunding Campaign

Epi One, a trailblazer in cancer diagnostics, is thrilled to announce the successful conclusion of its equity crowdfunding ...

Transforming Early Cancer Detection: Latest Webinar Highlights

At Epi One, we're on a mission to revolutionize how cancer is detected and diagnosed. During our recent ...

Join Us for Epi One’s Final Investment Webinar – A Conversation with CEO Michael Marquardt and Chief Scientist & Founder Dr. Fang

As our StartEngine campaign enters its final weeks, we're excited to invite you to a special webinar event ...

Epi One: Top Reasons to Invest Today

7 Reasons to Invest in Epi One: Transforming Cancer Detection Imagine a world where a simple test could ...

Webinar Recap: Transforming Lives Through Early Cancer Detection

At Epi One, we're on a mission to change the landscape of cancer detection. Our recent webinar, led ...

Market Opportunity with Epi One

Market Opportunity with Epi One We believe Epi One is at the vanguard of the rapidly evolving cancer ...

$1 Million Raised from Equity Crowdfunding

We are incredibly excited and humbled to announce that Epi One has now surpassed the $1 million mark ...

Scientific Breakthrough in the Lab

We are delighted to report that recent experiments have enabled us to identify biomarkers for lung, pancreatic, stomach ...
Scroll to Top